Stifel analyst Paul Mattels raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $41.00 (from $34.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE